Lexaria Bioscience Corp.

LEXX · NASDAQ
Analyze with AI
8/31/2025
8/31/2024
8/31/2023
8/31/2022
Operating Activities
Net Income-$11,911-$5,809-$6,713-$7,384
Dep. & Amort.$88$76$145$141
Deferred Tax$0$0-$158$0
Stock-Based Comp.$859$492$170$753
Change in WC$0$107$143-$351
Other Non-Cash$514$175$530$1,962
Operating Cash Flow-$10,450-$4,959-$5,881-$4,879
Investing Activities
PP&E Inv.$0$0-$34-$131
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.-$243-$189-$136-$49
Investing Cash Flow-$243-$189-$170-$181
Financing Activities
Debt Repay.$0$0$0-$45
Stock Issued$0$4,209$1,590$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$6,046$6,106$0$0
Financing Cash Flow$6,046$10,315$1,590-$45
Forex Effect-$51-$20$0$0
Net Chg. in Cash-$4,698$5,148-$4,461-$5,105
Supplemental Information
Beg. Cash$6,500$1,352$5,813$10,918
End Cash$1,802$6,500$1,352$5,813
Free Cash Flow-$10,450-$5,002-$6,051-$5,011
Lexaria Bioscience Corp. (LEXX) Financial Statements & Key Stats | AlphaPilot